Good morning, and welcome to the Jefferies 2025 Healthcare Conference. It's my pleasure now to introduce David Kirn, CEO; and Chris Simms, Chief Commercial Officer of 4D Molecular Therapeutics. All ...
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
SC25: Nvidia CPUs and GPUs dominate the bi-annual leaderboard, but FP64 performance regressions leave its long term ...
EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...
Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its chief executive officer, Gregory D. Kunst, will present preclinical data highlighting the ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
Interview: Nvidia's Ian Buck on the importance of FP64 to power research, in a world that's hot for inferencing ...
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.
A single intravitreal injection of 4D-150 helped patients with wet age-related macular degeneration maintain visual acuity ...
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
PCMag on MSN
Framework Laptop 16 (2025)
Framework's 16-inch model distinguishes itself from the 13-inch Framework Laptop with this feature, which has a separate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback